EU, US rosiglitazone decisions spark action in other countries
This article was originally published in SRA
Executive Summary
A number of countries have issued regulatory notices regarding rosiglitazone-containing products following last week's decision by the European Medicines Agency to suspend marketing authorisation for all such products and by the US Food and Drug Administration to impose severe new restrictions on the use of GlaxoSmithKline's rosiglitazone-containing drug, Avandia, because of potential cardiovascular risks associated with the drug1.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.